Rhumatologie

Sustained treatment by infliximab every 6 weeks is more efficacious than on-demand regimen in ankylosing spondylitis (AS): results of a one-year prospective randomized trial.

Poster – 69ème Congrès ACR – San Diego (Californie- USA) – 15-17/12/2005 Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller Ziegler L, Pham T, Flipo RM, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Saraux A, Mariette X, Baleydier A, Dougados M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Treat to target in axial spondyloarthritis: From its concept to its implementation
Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation